Vanda Pharms Inc patent expiration

1. Fanapt patent expiration

FANAPT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39198 VANDA PHARMS INC Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Nov, 2016

(7 years ago)

US9138432 VANDA PHARMS INC Methods for the administration of iloperidone
Sep, 2025

(1 year, 2 months from now)

US8586610 VANDA PHARMS INC Methods for the administration of iloperidone
Nov, 2027

(3 years from now)

US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Apr, 2030

(5 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype
Aug, 2030

(6 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Oct, 2030

(6 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2030

(6 years from now)

US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Jan, 2031

(6 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Feb, 2031

(6 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2014
M(M-180) May 26, 2019
New Indication(I-939) Apr 02, 2027

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Indicated for the acute treatment of adults with schizophrenia; Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with f...

Dosage: TABLET

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

2. Hetlioz patent expiration

HETLIOZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 7 months ago)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826339 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US8785492 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918556 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918557 VANDA PHARMS INC Treatment of circadian rhythm disorders
Apr, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(9 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2019
Orphan Drug Exclusivity(ODE) Jan 31, 2021
Orphan Drug Exclusivity(ODE-59) Jan 31, 2021
New Indication(I-850) Dec 01, 2023
Orphan Drug Exclusivity(ODE-330) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

NCE-1 date: 31 January, 2018

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-...

Dosage: CAPSULE

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Hetlioz Lq patent expiration

HETLIOZ LQ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 7 months ago)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918556 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11826339 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918557 VANDA PHARMS INC Treatment of circadian rhythm disorders
Apr, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(9 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 01, 2023
Orphan Drug Exclusivity(ODE-329) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttim...

Dosage: SUSPENSION

More Information on Dosage

HETLIOZ LQ family patents

Family Patents